Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Engineering cytokines for cancer immunotherapy: a systematic review
by
Zhao, Xiaofeng
, Tang, Renhong
, Fu, Yong
in
Antibodies
/ Antitumor activity
/ Biological products
/ Cancer
/ Cancer immunotherapy
/ Cancer therapies
/ Cell interactions
/ Circulatory system
/ Clinical trials
/ Cytokines
/ Cytokines - therapeutic use
/ Cytotoxicity
/ Drug dosages
/ Engineering
/ engineering cytokine
/ fusion protein
/ Humans
/ immunocytokine
/ Immunoglobulins
/ Immunology
/ Immunotherapy
/ Immunotherapy - methods
/ Medical research
/ Metastasis
/ Molecular weight
/ Mutation
/ Neoplasms - therapy
/ Pharmacokinetics
/ Polyethylene glycol
/ Polymers
/ prodrug cytokine
/ Proteins
/ Toxicity
/ Translation
/ Tumor Microenvironment
/ Tumor necrosis factor-TNF
/ Tumors
/ α-Interferon
2023
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Engineering cytokines for cancer immunotherapy: a systematic review
by
Zhao, Xiaofeng
, Tang, Renhong
, Fu, Yong
in
Antibodies
/ Antitumor activity
/ Biological products
/ Cancer
/ Cancer immunotherapy
/ Cancer therapies
/ Cell interactions
/ Circulatory system
/ Clinical trials
/ Cytokines
/ Cytokines - therapeutic use
/ Cytotoxicity
/ Drug dosages
/ Engineering
/ engineering cytokine
/ fusion protein
/ Humans
/ immunocytokine
/ Immunoglobulins
/ Immunology
/ Immunotherapy
/ Immunotherapy - methods
/ Medical research
/ Metastasis
/ Molecular weight
/ Mutation
/ Neoplasms - therapy
/ Pharmacokinetics
/ Polyethylene glycol
/ Polymers
/ prodrug cytokine
/ Proteins
/ Toxicity
/ Translation
/ Tumor Microenvironment
/ Tumor necrosis factor-TNF
/ Tumors
/ α-Interferon
2023
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Engineering cytokines for cancer immunotherapy: a systematic review
by
Zhao, Xiaofeng
, Tang, Renhong
, Fu, Yong
in
Antibodies
/ Antitumor activity
/ Biological products
/ Cancer
/ Cancer immunotherapy
/ Cancer therapies
/ Cell interactions
/ Circulatory system
/ Clinical trials
/ Cytokines
/ Cytokines - therapeutic use
/ Cytotoxicity
/ Drug dosages
/ Engineering
/ engineering cytokine
/ fusion protein
/ Humans
/ immunocytokine
/ Immunoglobulins
/ Immunology
/ Immunotherapy
/ Immunotherapy - methods
/ Medical research
/ Metastasis
/ Molecular weight
/ Mutation
/ Neoplasms - therapy
/ Pharmacokinetics
/ Polyethylene glycol
/ Polymers
/ prodrug cytokine
/ Proteins
/ Toxicity
/ Translation
/ Tumor Microenvironment
/ Tumor necrosis factor-TNF
/ Tumors
/ α-Interferon
2023
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Engineering cytokines for cancer immunotherapy: a systematic review
Journal Article
Engineering cytokines for cancer immunotherapy: a systematic review
2023
Request Book From Autostore
and Choose the Collection Method
Overview
Cytokines are pivotal mediators of cell communication in the tumor microenvironment. Multiple cytokines are involved in the host antitumor response, but the production and function of these cytokines are usually dysregulated during malignant tumor progression. Considering their clinical potential and the early successful use of cytokines in cancer immunotherapy, such as interferon alpha-2b (IFNα-2b; IntronA ® ) and IL-2 (Proleukin ® ), cytokine-based therapeutics have been extensively evaluated in many follow-up clinical trials. Following these initial breakthroughs, however, clinical translation of these natural messenger molecules has been greatly limited owing to their high-degree pleiotropic features and complex biological properties in many cell types. These characteristics, coupled with poor pharmacokinetics (a short half-life), have hampered the delivery of cytokines via systemic administration, particularly because of severe dose-limiting toxicities. New engineering approaches have been developed to widen the therapeutic window, prolong pharmacokinetic effects, enhance tumor targeting and reduce adverse effects, thereby improving therapeutic efficacy. In this review, we focus on the recent progress and competitive landscape in cytokine engineering strategies and preclinical/clinical therapeutics for cancer. In addition, aiming to promote engineered cytokine-based cancer immunotherapy, we present a profound discussion about the feasibility of recently developed methods in clinical medicine translation.
This website uses cookies to ensure you get the best experience on our website.